Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
SAN DIEGO, April 05, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Needham & Company 15th Annual Healthcare Conference in New York City on Tuesday, April 12, 2016 at 4:20 p.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell-based product pipeline is comprised of immuno-oncology therapies, including off-the-shelf NK- and T-cell-based candidates derived from engineered induced pluripotent cells, and immuno-regulatory therapies, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner Stern Investor Relations, Inc. 212.362.1200 [email protected]
